Mirabegron CAS:223673-61-8 Manufacturer Supplier

Mirabegron is for the treatment of urgency, urinary frequency, and urinary urge urinary incontinence associated with overactive bladder (OAB). Mirabegron is synthesized by coupling 4-nitrophenethyl amine to (R)-2-hydroxy-2-phenylacetic acid. The resulting amide is reduced to an amine. The nitro group is then reduced and the resulting is coupled to 2-(2-aminothiazol-4-yl) acetic acid to give mirabegron.

Order or Request Quote

Product Detail

Product Tags

Application and Effect

Mirabegron is an orally active β3-adrenoceptor agonist currently in development by Astellas Pharma for the treatment of overactive bladder (OAB). The drug is a nanomolar EC50 antagonist against human β3-AR biochemical assays with good selectivity over b1- and β2-ARs. Mirabegron demonstrates a novel mechanism by targeting the β3-AR for bladder relaxation to help manage OAB symptoms such as increased urinary urgency and frequency and urgency incontinence. However, mirabegron is a cytochrome P450 2D6 inhibitor, and it raises a concern for drug–drug interaction with concomitant administration of other cytochrome P450 2D6 substrates.

Product Sample

Product Packing:

Additional Information:

Composition	C21H24N4O2S
Assay	99%
Appearance	White to Pale Yellow powder
CAS No.	223673-61-8
Packing	25KG
Shelf Life	2 years
Storage	Store in cool and dry area
Certification	ISO.